Early Cessation of Sedation and TTM in Patients With a Favourable EEG After Cardiac Arrest
Launched by MEDISCH SPECTRUM TWENTE · Sep 20, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how safely and effectively doctors can reduce sedation and other life-support treatments for patients who have had a cardiac arrest but show a hopeful brain response on an EEG (a test that measures brain activity). The goal is to see if patients can start waking up and recovering sooner, specifically within 12 hours after their cardiac arrest, if their EEG shows a normal background pattern. By doing this, researchers hope to improve recovery times and outcomes for these patients.
To be eligible to participate in this trial, patients should be at least 18 years old and have been admitted to the ICU after a cardiac arrest. They must have had continuous EEG monitoring started within 12 hours of their cardiac arrest, showing a favorable pattern that suggests mild or no brain damage. Participants will be asked to stop sedative treatment shortly after identifying this positive EEG pattern, and they will be monitored closely for their safety and recovery. This trial is currently recruiting participants, and it aims to provide valuable insights into improving care for those who have suffered a cardiac arrest.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients after cardiac arrest admitted to the ICU for treatment with sedation, TTM and mechanical ventilation.
- • Age 18 years or older.
- • Continuous EEG measurement started within 12 hours after cardiac arrest.
- • Favourable EEG pattern within 12 hours after arrest, defined as a continuous background pattern (NVN, 2019; Ruijter et al., 2019).
- • Possibility to stop sedative treatment within three hours after identification of a favourable EEG pattern.
- • Written informed consent (deferred).
- Exclusion Criteria:
- • A known history of another medical condition with limited life expectancy (\<6 months).
- • Any progressive brain illness, such as a brain tumour or neurodegenerative disease.
- • Pre-admission Glasgow Outcome Scale Extended score of 4 or lower.
- • Reason other than neurological condition to continue sedation and/or ventilation.
- • Follow-up impossible due to logistic reasons.
About Medisch Spectrum Twente
Medisch Spectrum Twente (MST) is a leading healthcare institution located in the Netherlands, dedicated to providing high-quality medical care and advancing clinical research. As a regional hospital, MST is committed to improving patient outcomes through innovative treatment options and comprehensive clinical trials. The institution fosters collaboration among multidisciplinary teams of healthcare professionals, researchers, and academic partners, ensuring a robust environment for conducting research that adheres to the highest ethical standards. MST's focus on patient-centered care and its strategic initiatives in clinical research contribute significantly to the advancement of medical knowledge and the development of effective therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Enschede, , Netherlands
Arnhem, , Netherlands
Arnhem, Gelderland, Netherlands
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported